JP7328263B2 - 免疫調節化合物 - Google Patents

免疫調節化合物 Download PDF

Info

Publication number
JP7328263B2
JP7328263B2 JP2020571855A JP2020571855A JP7328263B2 JP 7328263 B2 JP7328263 B2 JP 7328263B2 JP 2020571855 A JP2020571855 A JP 2020571855A JP 2020571855 A JP2020571855 A JP 2020571855A JP 7328263 B2 JP7328263 B2 JP 7328263B2
Authority
JP
Japan
Prior art keywords
optionally substituted
mmol
cancer
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530453A (ja
JPWO2020006233A5 (enExample
Inventor
ナサナエル グレイ，
ティンフー ジャン，
エリック フィッシャー，
アリッサ ヴェラーノ，
ジーシャン ヒー，
グワンイェン ドゥ，
キャサリン ドノヴァン，
ラドスロー ノワク，
ジン ティン クリスティーン ユアン，
フー リウ，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2021530453A publication Critical patent/JP2021530453A/ja
Publication of JPWO2020006233A5 publication Critical patent/JPWO2020006233A5/ja
Priority to JP2023126807A priority Critical patent/JP2023145694A/ja
Application granted granted Critical
Publication of JP7328263B2 publication Critical patent/JP7328263B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020571855A 2018-06-29 2019-06-27 免疫調節化合物 Active JP7328263B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023126807A JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692176P 2018-06-29 2018-06-29
US62/692,176 2018-06-29
PCT/US2019/039509 WO2020006233A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126807A Division JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Publications (3)

Publication Number Publication Date
JP2021530453A JP2021530453A (ja) 2021-11-11
JPWO2020006233A5 JPWO2020006233A5 (enExample) 2022-07-05
JP7328263B2 true JP7328263B2 (ja) 2023-08-16

Family

ID=68987232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571855A Active JP7328263B2 (ja) 2018-06-29 2019-06-27 免疫調節化合物
JP2023126807A Pending JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023126807A Pending JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Country Status (8)

Country Link
US (1) US12234220B2 (enExample)
EP (1) EP3814330A4 (enExample)
JP (2) JP7328263B2 (enExample)
KR (1) KR102834593B1 (enExample)
CN (1) CN113166100A (enExample)
AU (1) AU2019293235B2 (enExample)
CA (1) CA3102212A1 (enExample)
WO (1) WO2020006233A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145694A (ja) * 2018-06-29 2023-10-11 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫調節化合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
AU2020392427B2 (en) * 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
IL293530A (en) 2019-12-18 2022-08-01 Novartis Ag Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
AR126052A1 (es) 2021-06-03 2023-09-06 Novartis Ag Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161119A1 (en) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161119A1 (en) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145694A (ja) * 2018-06-29 2023-10-11 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫調節化合物

Also Published As

Publication number Publication date
US20210284624A1 (en) 2021-09-16
KR20210027395A (ko) 2021-03-10
JP2023145694A (ja) 2023-10-11
KR102834593B1 (ko) 2025-07-16
AU2019293235A1 (en) 2020-12-17
CN113166100A (zh) 2021-07-23
US12234220B2 (en) 2025-02-25
WO2020006233A1 (en) 2020-01-02
CA3102212A1 (en) 2020-01-02
JP2021530453A (ja) 2021-11-11
EP3814330A4 (en) 2022-07-20
EP3814330A1 (en) 2021-05-05
AU2019293235B2 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
JP7328263B2 (ja) 免疫調節化合物
JP7321194B2 (ja) セレブロン（ｃｒｂｎ）に対するリガンド
JP7720833B2 (ja) Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
AU2019371400B2 (en) Acetylation writer inhibitor development and uses thereof
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
JP2023545396A (ja) Ｈｅｌｉｏｓのピペリジニル低分子分解剤および使用方法
CN113164475A (zh) Dyrk1a的大环抑制剂
AU2021227907A1 (en) Potent and selective degraders of ALK
CA3172589A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
EP4367115A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof
CN116669769A (zh) Helios的哌啶基小分子降解剂和使用方法
CN116801878A (zh) Her2的有效和选择性抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230803

R150 Certificate of patent or registration of utility model

Ref document number: 7328263

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150